Overview
Overview
HGH 191AA is recombinant human growth hormone (somatropin) identical to endogenous GH, studied extensively for its effects on body composition, metabolism, and tissue repair[1][7]. Clinical protocols typically employ subcutaneous administration once daily to mimic physiological GH secretion patterns[2][3]. This educational protocol presents a gradual titration approach using practical dilution for precise insulin-syringe measurements. Reconstitute: Add 3.0 mL bacteriostatic water → ~1.11 mg/mL
- Category
- Growth Hormone
- Routes
- subcutaneous
Mechanism
HGH 191AA
Mechanism of action
Mechanism of action
HGH 191AA is recombinant human growth hormone (somatropin) that is structurally identical to endogenous GH secreted by the pituitary gland [1] [5] . Clinical studies demonstrate that GH administration promotes increases in lean body mass, reductions in adipose tissue, and improvements in body composition through multiple mechanisms including enhanced lipolysis, increased protein synthesis, and stimulation of IGF-1 production [7] [8] . Pivotal research by Rudman and colleagues showed that six months of HGH administration in older men significantly increased lean body mass and decreased adipose mass compared to placebo [7] . Long-term follow-up studies in adults with GH deficiency have demonstrated sustained improvements in muscle strength and body composition with maintenance dosing [8] . Subcutaneous administration once daily, particularly at bedtime, is designed to mimic physiological patterns of endogenous GH secretion [2] [3] . Dosing protocols vary based on therapeutic goals: conservative replacement protocols typically employ 150–500 mcg daily [1] , while advanced metabolic and performance research protocols may utilize 1000–2000 mcg daily [4] . Higher doses produce more pronounced physiological effects but also carry increased risk of side effects including fluid retention, joint discomfort, and potential metabolic disturbances [2] .
Key research findings
- 01
Recombinant human growth hormone (somatropin): a 191-amino-acid protein (~22 kDa) with a sequence identical to the principal endogenous pituitary GH isoform (well-established endocrinology; human studies).
- 02
The '191AA' designation distinguishes it from the older 192-amino-acid methionyl variant (somatrem); the 191AA form matches native human GH (protein chemistry).
- 03
Acts directly at the GH receptor and indirectly by inducing hepatic IGF-1 production; unlike the secretagogues in this category, it supplies the hormone itself rather than stimulating its release (endocrinology; human study).
- 04
Recombinant somatropin is an extensively studied, approved prescription biologic in many jurisdictions for defined clinical indications (regulatory fact; stated here as background, not a treatment recommendation).
Primary source: Backed by an extensive, mature human evidence base spanning decades of endocrinology and clinical pharmacology on recombinant GH and the GH/IGF-1 axis. It is a well-characterized approved biologic rather than an experimental peptide.
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Protocol Reference
Protocol reference
Commonly cited research range: 150–2000 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Week 1
200 mcg
Week 2
300 mcg
Week 3
400 mcg
Week 4
500 mcg
Week 5
600 mcg
Week 6
700 mcg
Week 7
800 mcg
Week 8
900 mcg
| Phase | Reference amount | Units / volume |
|---|---|---|
| Week 1 | 200 mcg | 18 units (0.18 mL) |
| Week 2 | 300 mcg | 27 units (0.27 mL) |
| Week 3 | 400 mcg | 36 units (0.36 mL) |
| Week 4 | 500 mcg | 45 units (0.45 mL) |
| Week 5 | 600 mcg | 54 units (0.54 mL) |
| Week 6 | 700 mcg | 63 units (0.63 mL) |
| Week 7 | 800 mcg | 72 units (0.72 mL) |
| Week 8 | 900 mcg | 81 units (0.81 mL) |
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 02🧴Inject slowly down the vial wall; avoid foaming.
- 03💉Gently swirl/roll until dissolved (do not shake vigorously to preserve protein structure)[5].
- 04💧Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 05🔄Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Refrigerate at 2–8 °C (35.6–46.4 °F); stable for several weeks when stored properly [5] .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Avoid freeze–thaw cycles of reconstituted peptide, as freezing can denature the protein [5] .
Clinical Evidence
Clinical evidence
One of the most extensively studied recombinant hormones, with a large clinical and preclinical literature on body composition and metabolism.
Backed by an extensive, mature human evidence base spanning decades of endocrinology and clinical pharmacology on recombinant GH and the GH/IGF-1 axis. It is a well-characterized approved biologic rather than an experimental peptide.
- 01Recombinant human growth hormone (somatropin): a 191-amino-acid protein (~22 kDa) with a sequence identical to the principal endogenous pituitary GH isoform (well-established endocrinology; human studies).
- 02The '191AA' designation distinguishes it from the older 192-amino-acid methionyl variant (somatrem); the 191AA form matches native human GH (protein chemistry).
- 03Acts directly at the GH receptor and indirectly by inducing hepatic IGF-1 production; unlike the secretagogues in this category, it supplies the hormone itself rather than stimulating its release (endocrinology; human study).
- 04Recombinant somatropin is an extensively studied, approved prescription biologic in many jurisdictions for defined clinical indications (regulatory fact; stated here as background, not a treatment recommendation).
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to HGH 191AA.
- 01Pfizer (Genotropin) Prescribing Information — Adult GH deficiency dosing: recommended start 0.45–0.90 IU (0.15–0.30 mg) SC daily; maintenance dose seldom exceeds 4 IU (≈1.33 mg) daily View Source
- 02EMD Serono (Serostim) Prescribing Information — HIV-associated wasting dose: 0.1 mg/kg SC daily (up to ~6 mg/day); administer injections subcutaneously, preferably at bedtime View Source
- 03Medsafe NZ Data Sheet (Omnitrope) — Subcutaneous injection technique: site rotation to prevent lipoatrophy; recommends 0.15–0.30 mg per day to start in adults, titrating up to ~1.3 mg/day as needed View Source
- 04Hadzovic et al., Bosn. J. Basic Med. Sci. 2004 — GH usage and abuse review: moderate doses of GH (70–400 mcg in healthy adults) produce dose-dependent increases in lipolysis and fat oxidation View Sourceet al. (2004)
- 05Saizen® (somatropin) FDA Label — Lyophilized 191aa HGH is a sterile, white powder for SC or IM injection after reconstitution with bacteriostatic water; potency: 5 mg ≈ 15 IU and 8.8 mg ≈ 26.4 IU View Source
- 06Superior Peptide (Product Data) — HGH 191AA is provided as a lyophilized powder intended for subcutaneous (or intramuscular) injection after reconstitution with bacteriostatic water View Source
- 07Rudman et al., N. Engl. J. Med. 1990 — Pivotal study in older men: six months of HGH (0.03 mg/kg 3× weekly) significantly increased lean body mass and decreased adipose mass compared to placebo View Sourceet al. (1990)
- 08Götherström et al., J. Clin. Endocrinol. Metab. 2010 — 10-year adult GH deficiency follow-up: initial ~0.72 mg/day GH replacement (then reduced to ~0.37 mg/day long-term) led to sustained increases in muscle strength and improved body composition View Sourceet al. (2010)
- 09Sathiavageeswaran et al., Clin. Endocrinol. 2007 — Trial in 60–77 y/o adults: low-dose GH (~0.16 mg/day for 12 months) was administered to evaluate cognitive effects, illustrating a conservative dosing regimen View Sourceet al. (2007)
- 10Liu et al., Ann. Intern. Med. 2008 — Systematic review of GH in healthy athletes: GH administration increased lean body mass but did not significantly improve muscle strength or exercise performance View Sourceet al. (2008)
- 11CDC Vaccine Administration Guidelines — Subcutaneous injection technique: angle/site selection; no aspiration required for subcutaneous route View Source
- 12CDC Subcutaneous Injection Technique (PDF) — Technique diagram and site guidance for subcutaneous injections View Source
- 13NCBI Bookshelf — Best practices for injection: asepsis, preparation, and administration techniques View Source
- 14Pure Lab Peptides — HGH 191AA (10 IU / 3.33 mg) product page with quality and batch documentation View Source
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Has been studied in clinical research; on this platform it is handled strictly as a research material. Consult a licensed healthcare professional for any clinical decisions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| HGH 191AAthis | Recombinant human growth hormone (somatropin), a 191-amino-acid protein identical to endogenous GH, acting on GH receptors to drive IGF-1 production and influence growth, metabolism, and tissue repair. | subcutaneous | Investigational / RUO |
| IGF-1 LR3 | A modified analog of insulin-like growth factor-1 with reduced binding to IGF-binding proteins, giving a markedly extended half-life and prolonged activation of IGF-1 receptor anabolic signaling. | subcutaneous | Investigational / RUO |
| Ipamorelin | Binds to ghrelin receptors to stimulate pituitary gland to release growth hormone. Highly selective with minimal side effects. | subcutaneous | Investigational / RUO |
| Sermorelin | Binds to GHRH receptors to stimulate pulsatile GH release, mimicking natural patterns. Preserves feedback mechanisms. | subcutaneous | Investigational / RUO |
| Tesamorelin | Binds to GHRH receptors to stimulate endogenous GH production. Preferentially reduces abdominal fat accumulation. | subcutaneous | Investigational / RUO |
| HMG | A purified gonadotropin preparation providing combined FSH and LH activity, acting on gonadal receptors to support gametogenesis and steroidogenesis. | subcutaneous | Investigational / RUO |
| Kisspeptin | A neuroendocrine peptide that activates KISS1R (GPR54) on GnRH neurons to stimulate gonadotropin-releasing hormone secretion, a key upstream regulator of the reproductive axis. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
Recombinant human growth hormone (somatropin) with the full 191-amino-acid sequence identical to the body's own GH. Presented here as a research material; nothing here is medical advice or a treatment recommendation.
191AA is the native-length human GH sequence; the older 192-amino-acid form (somatrem) carried an extra N-terminal methionine. The 191AA form matches endogenous human GH.
GHRH analogs (e.g., sermorelin, CJC-1295, tesamorelin) and ghrelin-receptor agonists (GHRPs, ipamorelin, MK-677) prompt the pituitary to release the body's own GH. HGH 191AA is the growth hormone itself, acting directly at the GH receptor and via IGF-1.
Recombinant somatropin is an approved prescription biologic in many jurisdictions for specific indications; that is regulatory background only. It is not a dietary supplement and is prohibited in sport under the WADA list.
As a fragile protein it is generally refrigerated (2-8C), protected from light and excessive agitation, and not frozen once reconstituted unless the supplier specifies otherwise. Follow the product certificate and storage guidance.
Research- and label-reported ranges vary by context; this workspace does not provide dosing instructions or medical advice. Refer to qualified clinical sources and the protocol reference materials.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.